CRA addressed issues relating to commercial success in patent litigation on behalf of an innovator company commercializing a drug for a rare disease. CRA addressed sales growth, profitability, and performance relative to other treatments for the same rare condition. In addition, CRA considered the characteristics of the product enabled by the patent in suit, taking into account clinical trial findings, product advantages reflected in company and public materials, and the company’s marketing activities.
Trade Secret Litigation Watch: August 2025
In this Insights, CRA’s Intellectual Property Practice consultants take a closer look at trade secret case filings and developments from the first half of...